• AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment

    Source: NASDAQ US Markets / 19 May 2024 22:05:22   America/New_York

    (RTTNews) - The primary results from the Phase IIa COURSE trial showed that treatment with AstraZeneca and Amgen's Tezspire (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not sta https://www.nasdaq.com/articles/astrazeneca:-new-data-shows-tezspires-role-in-future-copd-treatment
Share on,